Clopidogrel: the blood thinner that needs an enzyme to switch it on
Clopidogrel is the pharmacogenomic case that convinced cardiology the field was real. The drug arrives in the body switched off, one enzyme switches it on, and if that enzyme runs slow the tablet does much less than the prescription assumes.
Also sold as: Plavix.
What clopidogrel is
Clopidogrel is an antiplatelet drug. It stops platelets clumping, which is what keeps a stent open and what lowers the chance of a second heart attack or stroke after a first one. It is taken daily, often for a year after a stent and sometimes indefinitely, and it is usually paired with aspirin in the early months.
Why your genes come into it
Clopidogrel is a prodrug. What you swallow has no antiplatelet effect at all until the liver converts a fraction of it into an active metabolite, and CYP2C19 does the decisive step in that conversion. Someone with two working copies of the gene makes the usual amount of active drug. Someone with reduced-function copies makes less of it, so their platelets stay more reactive on a standard 75 mg dose than the dose implies. The clinical consequence was measured in stent patients: reduced CYP2C19 function tracks with more cardiovascular events on clopidogrel. That evidence is why the FDA label carries a boxed warning about poor metabolizers, and why alternatives that do not need this enzyme exist in guidance.
What published guidance says
The rows below are CPIC's published guidance restated word for word, matched to each possible CYP2C19 result. They describe what a prescriber weighs, not what you should do. Clopidogrel is usually being taken for a specific and serious reason, and stopping an antiplatelet drug without the prescriber who started it is genuinely dangerous.
CYP2C19
| If your CYP2C19 result is | What that means | Published CPIC guidance |
|---|---|---|
| Intermediate Metabolizer | Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events | Per CPIC (A): "Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication." |
| Likely Intermediate Metabolizer | Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events | Per CPIC (A): "Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication." |
| Likely Poor Metabolizer | Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events | Per CPIC (A): "Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication." |
| Normal Metabolizer | Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity | Per CPIC (A): "If considering clopidogrel, use at standard dose (75 mg/day)" |
| Poor Metabolizer | Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events | Per CPIC (A): "Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication." |
| Rapid Metabolizer | Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk | Per CPIC (A): "If considering clopidogrel, use at standard dose (75 mg/day)" |
| Ultrarapid Metabolizer | Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk | Per CPIC (A): "If considering clopidogrel, use at standard dose (75 mg/day)" |
Can your DNA file answer this?
CYP2C19 is one of the pharmacogenes a consumer chip file can genuinely answer. The two common variants that carry most of the signal, the reduced-function *2 and the increased-function *17, are single positions that 23andMe and AncestryDNA arrays commonly include, so Aimosti reads this gene from the file you already have rather than only from aligned reads. The honest limits: rarer CYP2C19 alleles are not on the array and will read as reference, and if a defining position is missing from your export the file cannot tell the reference allele from a position that was never covered. Where the star alleles do not resolve, the result is reported as Indeterminate rather than guessed.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
I am on clopidogrel and my result is intermediate or poor metabolizer. What now?
Take the result to the prescriber who started it, and keep taking the drug in the meantime. Published guidance points toward prasugrel or ticagrelor for reduced metabolizers where there is no contraindication, but those alternatives carry their own bleeding profiles and are not suitable for everyone. That trade-off is the prescriber's to make with your full history in front of them.
Is clopidogrel testing standard practice?
It varies by country and by setting. Some cardiology services genotype routinely before or shortly after a stent, others test only when a patient has an event on treatment, and others do not test at all. The FDA boxed warning about poor metabolizers has been on the label since 2010, so the information is not new, but adoption has been uneven.
Does a normal metabolizer result mean clopidogrel is definitely working?
No. It means the most common genetic reason for it underperforming is absent. Platelet reactivity is affected by dose, adherence, drug interactions and other factors that have nothing to do with CYP2C19, and this result does not measure any of them.
What about omeprazole? I have read it interferes with clopidogrel.
Some proton pump inhibitors are handled by the same enzyme, which is where the interaction concern comes from, and it is a recognised question in prescribing rather than an internet rumour. It is also a separate matter from your genotype and worth raising directly with the prescriber or pharmacist who sees your whole medication list.
Can I use my old 23andMe file for this?
For CYP2C19, usually yes, which makes clopidogrel one of the better-answered questions from consumer data. Aimosti reads the file you already own instead of selling you a new test. Where the file does not resolve your star alleles, the report says Indeterminate rather than assuming the common result.